145 related articles for article (PubMed ID: 1694851)
1. High molecular weight kininogen-binding site of prekallikrein probed by monoclonal antibodies.
Hock J; Vogel R; Linke RP; Müller-Esterl W
J Biol Chem; 1990 Jul; 265(20):12005-11. PubMed ID: 1694851
[TBL] [Abstract][Full Text] [Related]
2. Mapping of the discontinuous kininogen binding site of prekallikrein. A distal binding segment is located in the heavy chain domain A4.
Herwald H; Renné T; Meijers JC; Chung DW; Page JD; Colman RW; Müller-Esterl W
J Biol Chem; 1996 May; 271(22):13061-7. PubMed ID: 8662705
[TBL] [Abstract][Full Text] [Related]
3. Mapping of the high molecular weight kininogen binding site of prekallikrein. Evidence for a discontinuous epitope formed by distinct segments of the prekallikrein heavy chain.
Herwald H; Jahnen-Dechent W; Alla SA; Hock J; Bouma BN; Müller-Esterl W
J Biol Chem; 1993 Jul; 268(19):14527-35. PubMed ID: 7686159
[TBL] [Abstract][Full Text] [Related]
4. Mapping of the prekallikrein-binding site of human H-kininogen by ligand screening of lambda gt11 expression libraries. Mimicking of the predicted binding site by anti-idiotypic antibodies.
Vogel R; Kaufmann J; Chung DW; Kellermann J; Müller-Esterl W
J Biol Chem; 1990 Jul; 265(21):12494-502. PubMed ID: 1695630
[TBL] [Abstract][Full Text] [Related]
5. Localization of distinct functional domains on prekallikrein for interaction with both high molecular weight kininogen and activated factor XII in a 28-kDa fragment (amino acids 141-371).
Page JD; Colman RW
J Biol Chem; 1991 May; 266(13):8143-8. PubMed ID: 1708772
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody to human high-molecular-weight kininogen recognizes its prekallikrein binding site and inhibits its coagulant activity.
Reddigari SR; Kaplan AP
Blood; 1989 Aug; 74(2):695-702. PubMed ID: 2752143
[TBL] [Abstract][Full Text] [Related]
7. Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain.
Thompson RE; Mandle R; Kaplan AP
Proc Natl Acad Sci U S A; 1979 Oct; 76(10):4862-6. PubMed ID: 291905
[TBL] [Abstract][Full Text] [Related]
8. The shape of high molecular weight kininogen. Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy.
Weisel JW; Nagaswami C; Woodhead JL; DeLa Cadena RA; Page JD; Colman RW
J Biol Chem; 1994 Apr; 269(13):10100-6. PubMed ID: 8144509
[TBL] [Abstract][Full Text] [Related]
9. A monoclonal anti-human plasma prekallikrein antibody that inhibits activation of prekallikrein by factor XIIa on a surface.
Veloso D; Silver LD; Hahn S; Colman RW
Blood; 1987 Oct; 70(4):1053-62. PubMed ID: 2443201
[TBL] [Abstract][Full Text] [Related]
10. Immunochemical studies of human high molecular weight kininogen and of its complexes with plasma prekallikrein or kallikrein.
Kerbiriou DM; Bouma BN; Griffin JH
J Biol Chem; 1980 May; 255(9):3952-8. PubMed ID: 6154706
[TBL] [Abstract][Full Text] [Related]
11. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2.
Renné T; Dedio J; Meijers JC; Chung D; Müller-Esterl W
J Biol Chem; 1999 Sep; 274(36):25777-84. PubMed ID: 10464316
[TBL] [Abstract][Full Text] [Related]
12. Fine mapping of the H-kininogen binding site in plasma prekallikrein apple domain 2.
Renné T; Sugiyama A; Gailani D; Jahnen-Dechent W; Walter U; Müller-Esterl W
Int Immunopharmacol; 2002 Dec; 2(13-14):1867-73. PubMed ID: 12489801
[TBL] [Abstract][Full Text] [Related]
13. Parallel mechanisms of high molecular weight kininogen action as a cofactor in kallikrein inactivation and prekallikrein activation reactions.
Olson ST; Francis AM; Sheffer R; Choay J
Biochemistry; 1993 Nov; 32(45):12148-59. PubMed ID: 8218292
[TBL] [Abstract][Full Text] [Related]
14. Mapping of functional domains of human high molecular weight and low molecular weight kininogens using murine monoclonal antibodies.
Ishiguro H; Higashiyama S; Ohkubo I; Sasaki M
Biochemistry; 1987 Nov; 26(22):7021-9. PubMed ID: 2447941
[TBL] [Abstract][Full Text] [Related]
15. Structural dissection of the multidomain kininogens. Fine mapping of the target epitopes of antibodies interfering with their functional properties.
Kaufmann J; Haasemann M; Modrow S; Müller-Esterl W
J Biol Chem; 1993 Apr; 268(12):9079-91. PubMed ID: 7682558
[TBL] [Abstract][Full Text] [Related]
16. Mapping of the H-kininogen binding site exposed by the prekallikrein heavy chain.
Herwald H; Hock H; Jahnen-Dechent W; Müller-Esterl W
Agents Actions Suppl; 1992; 38 ( Pt 1)():225-32. PubMed ID: 1466274
[No Abstract] [Full Text] [Related]
17. Functional domains in the heavy-chain region of factor XI: a high molecular weight kininogen-binding site and a substrate-binding site for factor IX.
Baglia FA; Sinha D; Walsh PN
Blood; 1989 Jul; 74(1):244-51. PubMed ID: 2665835
[TBL] [Abstract][Full Text] [Related]
18. Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein.
Wiggins RC; Bouma BN; Cochrane CG; Griffin JH
Proc Natl Acad Sci U S A; 1977 Oct; 74(10):4636-40. PubMed ID: 270705
[TBL] [Abstract][Full Text] [Related]
19. Localization of the binding site on plasma kallikrein for high-molecular-weight kininogen to both apple 1 and apple 4 domains of the heavy chain.
Page JD; You JL; Harris RB; Colman RW
Arch Biochem Biophys; 1994 Oct; 314(1):159-64. PubMed ID: 7944388
[TBL] [Abstract][Full Text] [Related]
20. Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.
Meier HL; Pierce JV; Colman RW; Kaplan AP
J Clin Invest; 1977 Jul; 60(1):18-31. PubMed ID: 874082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
